Polymorphisms in the CPB2 gene are maintained by balancing selection and result in haplotype-preferential splicing of exon 7

Molecular Biology and Evolution

Volumn 27, Issue 8, 2010, Pages 1945-1954

  Cagliani, Rachele ^a   Fumagalli, Matteo ^a,b   Riva, Stefania ^a   Pozzoli, Uberto ^a   Fracassetti, Marco ^a   Bresolin, Nereo ^a,c   Comi, Giacomo P ^c   Sironi, Manuela ^a  

^a SCIENTIFIC INSTITUTE   (Italy)

^b POLITECNICO DI MILANO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

alternative splicing; balancing selection; CPB2; thrombin activatable fibrinolysis inhibitor

Indexed keywords

NUCLEOTIDE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; PROTEIN PRECURSOR;

ALTERNATIVE RNA SPLICING; ARTICLE; CELL STRAIN HEPG2; CPB2 GENE; EXON; EXON SKIPPING; FIBRINOLYSIS; GENE; GENE SEQUENCE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN TISSUE; LIVER; MOLECULAR EVOLUTION; PATHOPHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SPLICING DEFECT; GENETIC DATABASE; GENETIC POLYMORPHISM; GENETIC SELECTION; GENETICS; INTRON; MOLECULAR GENETICS; POPULATION GENETICS;

ALTERNATIVE SPLICING; CARBOXYPEPTIDASE B2; DATABASES, GENETIC; EXONS; GENETIC VARIATION; GENETICS, POPULATION; HAPLOTYPES; HUMANS; INTRONS; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; PROTEIN PRECURSORS; SELECTION, GENETIC;

EID: 77955000813     PISSN: 07374038     EISSN: 15371719     Source Type: Journal    
DOI: 10.1093/molbev/msq082     Document Type: Article

References (55)

1. Alonso S, Lopez S, Izagirre N, de la Rua C. 2008. Overdominance in the human genome and olfactory receptor activity. Mol Biol Evol. 25:997-1001.
2. Bandelt HJ, Forster P, Rohl A. 1999. Median-joining networks for inferring intraspecific phylogenies. Mol Biol Evol. 16:37-48.
3. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
4. Biswas A, Tiwari AK, Ranjan R, Meena A, Akhter MS, Yadav BK, Behari M, Saxena R. 2009. Prothrombotic polymorphisms, mutations, and their association with pediatric non-cardioembolic stroke in asian-indian patients. Ann Hematol. 88:473-478.
5. Boffa MB, Koschinsky ML. 2007. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem. 40:431-442.
6. Boffa MB, Maret D, Hamill JD, et al. (12 co-authors). 2008. Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis. Blood. 111:183-189.
7. Boffa MB, Wang W, Bajzar L, Nesheim ME. 1998. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem. 273:2127-2135.
8. Buelens K, Hillmayer K, Compernolle G, Declerck PJ, Gils A. 2008. Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor. Circ Res. 102:295-301. (Pubitemid 351271649)
9. Bustamante CD, Fledel-Alon A, Williamson S, et al. (14 co-authors). 2005. Natural selection on protein-coding genes in the human genome. Nature 437:1153-1157.
10. Cagliani R, Fumagalli M, Pozzoli U, Riva S, Comi GP, Torri F, Macciardi F, Bresolin N, Sironi M. 2009. Diverse evolutionary histories for beta-adrenoreceptor genes in humans. Am J Hum Genet. 85:64-75.
11. Campbell WD, Lazoura E, Okada N, Okada H. 2002. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol. 46:131-134.
12. Ceresa E, De Maeyer M, Jonckheer A, Peeters M, Engelborghs Y, Declerck PJ, Gils A. 2007. Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability. J Thromb Haemost. 5:2105-2112.
13. Ceresa E, Van de Borne K, Peeters M, Lijnen HR, Declerck PJ, Gils A. 2006. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant. J Biol Chem. 281: 15878-15883.
14. de Bruijne EL, Darwish Murad S, de Maat MP, Tanck MW, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HL, Leebeek FW. Liver and Thrombosis Study Group. 2007. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. Thromb Haemost. 97:181-185.
15. Dempfle CE, Borggrefe M. 2009. Thrombin-activatable fibrinolysis inhibitor-a inhibitors: drugs for sepsis or drugs for disseminated intravascular coagulation? Crit Care Med. 37:1823-1824.
16. Evans PD, Gilbert SL, Mekel-Bobrov N, Vallender EJ, Anderson JR, Vaez-Azizi LM, Tishkoff SA, Hudson RR, Lahn BT. 2005. Microcephalin, a gene regulating brain size, continues to evolve adaptively in humans. Science 309:1717-1720.
17. Fu YX, Li WH. 1993. Statistical tests of neutrality of mutations. Genetics. 133:693-709.
18. Glazko GV, Nei M. 2003. Estimation of divergence times for major lineages of primate species. Mol Biol Evol. 20:424-434.
19. Griffiths RC, Tavare S. 1994. Ancestral inference in population genetics. Stat Sci. 9:307-319.
20. Griffiths RC, Tavare S. 1995. Unrooted genealogical tree probabilities in the infinitely-many-sites model. Math Biosci. 127:77-98.
21. Henry M, Aubert H, Morange PE, Nanni I, Alessi MC, Tiret L, Juhan-Vague I. 2001. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 97:2053-2058.
22. Hudson RR, Kreitman M, Aguade M. 1987. A test of neutral molecular evolution based on nucleotide data. Genetics 116:153-159.
23. Hurst LD. 2009. Fundamental concepts in genetics: genetics and the understanding of selection. Nat Rev Genet. 10:83-93.
24. Juhan-Vague I, Morange PE, Aubert H, et al. (14 co-authors). 2002. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of europe. Arterioscler Thromb Vasc Biol. 22:867-873.
25. Kimura M. 1983. The neutral theory of molecular evolution. Cambridge: Cambridge University Press.
26. Martini CH, Brandts A, de Bruijne EL, van Hylckama Vlieg A, Leebeek FW, Lisman T, Rosendaal FR 2006 The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol. 134:92-94.
27. Marx PF, Brondijk TH, Plug T, Romijn RA, Hemrika W, Meijers JC, Huizinga EG. 2008. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation. Blood 112:2803-2809.
28. Marx PF, Havik SR, Marquart JA, Bouma BN, Meijers JC. 2004. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem. 279:6620-6628.
29. Matsumoto A, Itoh K, Matsumoto R. 2000. A novel carboxy-peptidase B that processes native beta-amyloid precursor protein is present in human hippocampus. Eur J Neurosci. 12:227-238.
30. Morange PE, Juhan-Vague I, Scarabin PY, et al. (11 co-authors). 2003. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME study (prospective epidemiological study of MI). Thromb Haemost. 89:554-560.
31. Morange PE, Tregouet DA, Frere C, et al. (13 co-authors). 2005. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME study. J Thromb Haemost. 3:1503-1510.
32. Morral N, Bertranpetit J, Estivill X, Nunes V, Casals T, Giménez J, Reis A, Varon-Mateeva R, Macek M Jr, Kalaydjieva L. 1994. The origin of the major cystic fibrosis mutation (delta F508) in European populations. Nat Genet. 8:216.
33. Mosnier LO, Bouma BN. 2006. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol. 26:2445-2453.
34. Muto Y, Suzuki K, Iida H, Sakakibara S, Kato E, Itoh F, Kakui N, Ishii H. 2009. EF6265, a novel inhibitor of activated thrombin-activatable fibrinolysis inhibitor, protects against sepsis-induced organ dysfunction in rats. Crit Care Med. 37:1744-1749.
35. Myles T, Nishimura T, Yun TH, Nagashima M, Morser J, Patterson AJ, Pearl RG, Leung LL. 2003. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J Biol Chem. 278:51059-51067.
36. Nei M. 1987. Molecular evolutionary genetics. New York: Columbia University Press.
37. Nei M, Li WH. 1979 Mathematical model for studying genetic variation in terms of restriction endonucleases. Proc Natl Acad Sci USA. 76:5269-5273.
38. R Development Core Team. 2008. R: a language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing.
39. Saillard J, Forster P, Lynnerup N, Bandelt HJ, Norby S 2000 mtDNA variation among Greenland Eskimos: the edge of the Beringian expansion. Am J Hum Genet. 67:718-722.
40. Sanglas L, Valnickova Z, Arolas JL, Pallares I, Guevara T, Sola M, Kristensen T, Enghild JJ, Aviles FX, Gomis-Ruth FX. 2008. Structure of activated thrombin-activatable fibrinolysis inhibitor, a molecular link between coagulation and fibrinolysis. Mol Cell. 31:598-606.
41. Sato T, Miwa T, Akatsu H, Matsukawa N, Obata K, Okada N, Campbell W, Okada H. 2000. Pro-carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase N is not. J Immunol. 165:1053-1058.
42. Schaffner SF, Foo C, Gabriel S, Reich D, Daly MJ, Altshuler D. 2005. Calibrating a coalescent simulation of human genome sequence variation. Genome Res. 15:1576-1583. (Pubitemid 41545011)
43. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. 2002. Two naturally occurring variants of TAFI (thr-325 and ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem. 277:1021-1030.
44. Stephens M, Scheet P. 2005. Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet. 76:449-462.
45. Tajima F. 1989. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 123:585-595.
46. te Velde EA, Wagenaar GT, Reijerkerk A, Roose-Girma M, Borel Rinkes IH, Voest EE, Bouma BN, Gebbink MF, Meijers JC. 2003. Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost. 1:2087-2096.
47. Thomson R, Pritchard JK, Shen P, Oefner PJ, Feldman MW. 2000. Recent common ancestry of human Y chromosomes: evidence from DNA sequence data. Proc Natl Acad Sci USA. 97:7360-7365.
48. Thornton K. 2003. Libsequence: a C\+\+ class library for evolutionary genetic analysis. Bioinformatics 19:2325-2327.
49. Tishkoff SA, Verrelli BC. 2003. Patterns of human genetic diversity: implications for human evolutionary history and disease. Annu Rev Genomics Hum Genet. 4:293-340.
50. Wang J, Song L, Grover D, Azrak S, Batzer MA, Liang P. 2006. dbRIP: a highly integrated database of retrotransposon insertion polymorphisms in humans. Hum Mutat. 27:323-329.
51. Watson RS, Carcillo JA. 2005. Scope and epidemiology of pediatric sepsis. Pediatr Crit Care Med. 6:S3-S5.
52. Watterson GA. 1975. On the number of segregating sites in genetical models without recombination. Theor Popul Biol. 7:256-276.
53. Willemse JL, Hendriks DF. 2006. Measurement of procarboxypepti-dase U (TAFI) in human plasma: a laboratory challenge. Clin Chem. 52:30-36.
54. Wu C, Kim PY, Manuel R, Seto M, Whitlow M, Nagashima M, Morser J, Gils A, Declerck P, Nesheim ME. 2009. The roles of selected arginine and lysine residues of TAFI (pro-CPU) in its activation to TAFIa by the thrombin-thrombomodulin complex. J Biol Chem. 284:7059-7067.
55. Xue Y, Daly A, Yngvadottir B, et al. (14 co-authors). 2006. Spread of an inactive form of caspase-12 in humans is due to recent positive selection. Am J Hum Genet. 78:659-670.